[Current aspects in organ transplantation].
A short review of the history of transplantation and classical immunosuppressive therapy with azathioprine and steroids is given. With the advent of more selective immuno-suppressants such as cyclosporin and monoclonal antibodies, a new era of immunomodulation began. The author summarizes recent experimental data showing that cyclosporin inhibits both the production of interleukin 2 and the formation of its membrane receptor. At the molecular level this effect might be achieved by binding to cyclophilin. The impact of immunomodulating agents, especially cyclosporin, for solid organ transplants, is substantial, although tolerance is not obtained. Finally, experimental drug development in pharmaceutical research is reviewed.